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Surgical Myectomy
Versus Alcohol Septal Ablation for
Obstructive Hypertrophic Cardiomyopathy
Will There Ever Be a Randomized Trial?
Iacopo Olivotto, MD,* Steve R. Ommen, MD,† Martin S. Maron, MD,§
Franco Cecchi, MD,* Barry J. Maron, MD‡
Florence, Italy; Rochester and Minneapolis, Minnesota; and Boston, Massachusetts
Dynamic left ventricular outflow tract obstruction is an important pathophysiologic feature of hypertrophic car-
diomyopathy (HCM) and a predictor of clinical deterioration and cardiovascular mortality. Patients with marked
obstruction and severe limiting symptoms refractory to maximum medical management are considered candi-
dates for invasive septal reduction therapy, which includes surgical myectomy and alcohol septal ablation (ASA).
Availability of both surgical myectomy and ASA has polarized the cardiovascular community concerning the
most appropriate implementation of these two interventions. The ensuing controversy of whether myectomy and
ASA are truly equivalent options has resulted in calls for a prospective randomized trial. However, upon analysis, such
a myectomy versus ASA trial, adequately powered to compare the key issue of long-term outcome, poses a myriad of
practical problems that seem virtually insurmountable. Therefore, it is appropriate to revisit this evolving debate at
this time, identify the unique obstacles to a randomized study design, and achieve some clarity concerning the most
realistic clinical strategies for symptomatic patients with HCM and outflow obstruction. (J Am Coll Cardiol 2007;50:
831–4) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.05.018B
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cn important and highly visible subgroup of patients with
ypertrophic cardiomyopathy (HCM) develop symptoms of
rogressive heart failure associated with obstruction to left
entricular (LV) outflow (1–4). Since its initial clinical
escription in the 1960s, surgical septal myectomy has been
he primary treatment option for reversing heart failure and
estoring acceptable quality of life in obstructive patients
ith drug-refractory symptoms (1,4–8). However, over the
ast 5 to 7 years, the percutaneous alternative of alcohol
eptal ablation (ASA) has been actively promoted for
atients with obstructive HCM (1,4,9,10).
The controversy of whether myectomy and ASA are truly
quivalent options, in terms of efficacy and outcome, has
eceived considerable attention within the cardiovascular
ommunity, frequently resulting in a call for definitive
andomized trials (1,11). Therefore, it is appropriate to
evisit this important evolving debate, particularly to iden-
ify unique obstacles to a randomized study design.
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echanism of obstruction and treatment. Left ventricu-
ar outflow tract obstruction is present at rest in approxi-
ately 25% of HCM patients (4). In addition, 50% of
atients without obstruction at rest can generate significant
ntraventricular gradients with exercise (12). Mechanical
mpedance to outflow in HCM typically occurs at the
ubaortic level, owing to mitral valve systolic anterior
otion (SAM) and mid-systolic contact with ventricular
eptum, associated with mitral regurgitation due to incom-
lete leaflet coaptation (4). In patients in whom LV outflow
ract obstruction is associated with heart failure symptoms,
onventional pharmacologic treatment with beta-blocking
gents, verapamil, or disopyramide might improve func-
ional limitation (4). In those patients with severe limiting
ymptoms refractory to maximum medical management and
arked outflow obstruction (peak instantaneous gradient
50 mm Hg at rest or with physiologic [exercise] provo-
ation) invasive treatment options to relieve the subaortic
radient should be considered (i.e., myectomy or, selec-
ively, ASA) (4,6–10).
yectomy. Surgical septal myectomy has been an estab-
ished treatment in HCM for almost 50 years (4–6). The
lassical technique involves resection of a discrete portion of
ypertrophied muscle from the basal septum, via transaortic
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prefer an extended muscular re-
section and might perform addi-
tional procedures such as mitral
valve repair or plication (6). Over
the last 10 years, surgical mortal-
ity related to isolated myectomy
has approached zero at major
North American centers (6–8).
Myectomy permanently abol-
ishes or markedly reduces LV
outflow gradient (and mitral re-
gurgitation), leading to substan-
tial improvement in symptoms in
the vast majority of patients (4–
). Surgical relief of obstruction confers long-term survival
quivalent to that of the general population (7,8) as well as
mproved quality of life.
SA. Alcohol septal ablation has experienced rapidly in-
reasing popularity since its recent introduction (4,9,10),
argely because it is seemingly less invasive than surgery and
ore accessible outside HCM referral centers. Penetration
f ASA into cardiologic practice has been so striking,
ompared with surgery, as to raise the possibility that a
owered threshold for selection of patients might be em-
loyed (6).
Alcohol septal ablation achieves relief of the subaortic
radient, which is mediated by a chemically induced myo-
ardial infarction (13), leading to reduced septal thickness
nd outflow tract remodeling (9,10). Accordingly, ASA
elieves heart failure-related symptoms in most patients,
lthough approximately 20% might require repeated proce-
ures (9,10,14–17). Procedural mortality for ASA is some-
hat higher than for surgery at HCM referral institutions
ver the last decade (6).
After ASA, clinical observations have unavoidably been
onfined to approximately 2-year mean follow-up periods,
recluding truly long-term outcome assessments (9,10,14–
7). Consequently, a number of specific issues remain
nresolved, predominantly related to the significance of
SA-intramyocardial scars as potentially arrhythmogenic
ubstrates (18–20).
he debate: bypass surgery versus angioplasty revisited?
vailability of both surgical myectomy and ASA has polar-
zed the cardiovascular community regarding the most
ppropriate implementation of these 2 interventions
1,5,6,11,21). Institutions offering both treatments advocate
yectomy as the gold standard for severely symptomatic
atients with outflow obstruction and regard ASA as an
mportant alternative for selected patients (1,5,6). Conversely,
any interventional cardiologists consider ASA to be the
rimary treatment option (21). The resulting myectomy versus
SA controversy presently represents a crossroads in the
volving management strategy for obstructive HCM.
It has been repeatedly asserted that this debate can only
Abbreviations
and Acronyms
ASA  alcohol septal
ablation
CABG  coronary artery
bypass graft surgery
HCM  hypertrophic
cardiomyopathy
LV  left ventricular
PTCA  percutaneous
transluminal coronary
angioplasty
SAM  systolic anterior
motione resolved with a prospective and randomized study sys- pematically comparing the 2 techniques (1,11). Indeed, it is
empting to promote a myectomy versus ASA trial, drawing
historical parallel with prior controversy surrounding coro-
ary artery bypass graft surgery (CABG) versus percutaneous
ransluminal coronary angioplasty (PTCA) (22–24). If ran-
omized trials for the invasive management of atherosclerotic
oronary artery disease were possible, then why not translate
his experience to HCM? However, close inspection of the
ata suggests this is not a tenable argument.
oronary artery disease. To compare long-term results of
ABG versus PTCA, 13 randomized clinical trials were
onducted, involving approximately 8,000 patients, with a
ong and challenging enrollment processes (22–24). Even-
ually, enrolled patients comprised12% of those originally
creened (24). Such low rates were due largely to patient or
hysician preferences for either treatment strategy, as evi-
enced in the BARI (Bypass Angioplasty Revascularization
nvestigation) and EAST (Emory Angioplasty Versus Sur-
ery Trial) studies (22,23), in which about 60% of eligible
atients refused randomization.
CM. Although HCM is the most common genetic heart
isease, it is relatively uncommon within the general pop-
lation. Given the estimated prevalence of 1:500, the
umber of HCM patients in the U.S. is approximately
00,000, including many who have not achieved clinical
ecognition (25). Of these, only a minority have an indica-
ion for invasive relief of obstruction (4). Thus, even with a
ulticenter study design, the number of patients available
or pre-randomization screening would be relatively small
nd only a fraction of that in CABG versus PTCA trials.
Furthermore, owing to the substantial heterogeneity of
he HCM disease spectrum, several clinical variables poten-
ially represent exclusion criteria for either myectomy or
SA, constituting an obstacle to randomization. Of these,
he most important is age. Most investigators would oppose
andomization of children, adolescents, or young adults, given
he long risk period ahead and lack of data regarding long-term
utcome of ASA (4,6). Also, randomization would not be
cceptable in the presence of compelling indications to surgical
yectomy (such as correction of mitral valve apparatus abnor-
alities, CABG, or the MAZE procedure for atrial fibrilla-
ion) (6) or to percutaneous ASA (such as particularly advanced
ge or significant comorbidity) (4).
s a randomized study feasible? Short-term issues such as
cute complication rates, magnitude of gradient reduction,
nd early symptomatic benefit have been largely resolved for
oth myectomy and ASA by virtue of available observa-
ional data (4,9,10,13–17). Therefore, it would seem unjus-
ified to conduct an expensive and difficult multicenter
andomized trial only to confirm what is already known.
ndeed, the major unanswered question in this debate
oncerns the comparison of long-term outcome for the 2
eptal reduction therapies (6).
However, a randomized myectomy versus ASA trial,
dequately powered to compare outcome as the primary end
oint, poses a myriad of practical obstacles, which seem
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August 28, 2007:831–4 Myectomy Versus Alcohol Ablation for HCMirtually insurmountable. First, given the low event rates
fter either procedure, very large study cohorts would be
equired to detect differences in survival (or lack thereof).
or example, assuming a 1% annual cardiovascular mortality
ate over a 5-year follow-up (including procedural deaths,
udden cardiac or heart failure deaths, and surrogates such
s appropriate implantable cardioverter-defibrillator inter-
entions and heart transplantation) (2,7,8), approximately
,200 patients with obstructive HCM and severe drug-
efractory symptoms would be required to detect a doubling
f annual mortality (to 2%) with a beta error rate of 10% at
he 2-sided alpha level of 0.05, even assuming that none of
he patients withdraw from the study or are lost to
ollow-up (26).
Enrolment of 1,200 suitable candidates (600 in each
reatment arm) would require initial screening of as many as
4,000 consecutive patients with HCM (Fig. 1). Of these,
10% (i.e., 3,400) (27) would initially qualify for invasive
eptal reduction, by virtue of marked LV outflow obstruc-
ion (usually present under resting conditions, but occasion-
lly only with physiologic provocation) associated with
evere heart failure (4,12). Of these 3,400 candidates, at
east 30% would likely have 1 or more trial exclusion criteria
n the basis of the aforementioned considerations for age
nd/or compelling indications for either myectomy or ASA
4,6). Of the remaining 2,400 patients, 50% would be
xpected to refuse randomization, on the basis of the prior
Figure 1 Estimates for a Theoretical Surgical Myectomy Versus
Flow diagrams comparing patient selection and recruitment in the BARI study (coro
plasty [PTCA]): a representative example of a coronary artery disease-related rando
(ASA) trial (right). HCM  hypertrophic cardiomyopathy.xperience with coronary intervention trials (22–24). There- sore, the 1,200 patients available for randomization would
ltimately represent only 3.5% of those initially screened.
Such an HCM population required for screening (i.e.,
4,000) largely exceeds the size of the combined cohorts
resently followed at major North American and European
eferral centers (2,3,8 –10,15,16). Nevertheless, smaller
ample sizes would fail to reach the desired statistical power,
nless the follow-up period could be extended substantially
e.g., to 10 to 20 years)—an unrealistic consideration.
onclusions and Future Perspectives
n adequately powered randomized trial comparing long-
erm benefits of myectomy and ASA in severely symptom-
tic patients with obstructive HCM is not feasible and
nlikely to be undertaken at any time. Alternative strategies
ould include carefully conducted prospective, non-
andomized studies assessing the long-term clinical out-
ome associated with both procedures, with particular re-
ard to the risk of late sudden cardiac death. Such robust
ong-term observational data could be assembled through a
tandardized multicenter registry, possibly under the aus-
ices and with the support of the National Heart, Lung, and
lood Institute. Similar successful registries have been
reated in the past for uncommon conditions, such as
rimary pulmonary hypertension. Indeed, although ran-
omized study designs represent the indisputable gold
Trial
rtery bypass graft surgery [CABG] vs. percutaneous transluminal coronary angio-
trial (23) (left) and a hypothetical myectomy versus alcohol septal ablationASA
nary a
mizedtandard for comparing competing treatment modalities,
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Myectomy Versus Alcohol Ablation for HCM August 28, 2007:831–4ell-conducted prospective observational studies can pro-
ide valid insights when randomization is not feasible (28).
Until that time when these issues have achieved greater
larity, it would seem most prudent to acknowledge the
ecommendations of the American College of Cardiology/
uropean Society of Cardiology expert consensus panel on
he management of HCM (4). Under these guidelines,
urgical septal myectomy represents the primary treatment
ption for most severely symptomatic, drug-refractory pa-
ients with obstructive HCM. Alcohol septal ablation is an
mportant treatment alternative for patients at increased
perative risk, without access to expert surgical centers, or
ho refuse operation after both options have been discussed
quitably (4).
Finally, it is highly desirable for both myectomy and ASA
o be performed at referral centers with comprehensive
linical expertise in HCM, where both therapies are avail-
ble. The choice between myectomy and ASA should be
ade by patients in concert with their cardiologist, on the
asis of consensus guidelines; their individual clinical pro-
le; and a full, unbiased, and evidence-based disclosure of
he advantages and disadvantages of each septal reduction
reatment.
eprint requests and correspondence: Dr. Iacopo Olivotto,
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